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ABSTRACT
A novel HybProbe real-time LightCycler PCR assay was developed for conﬁrmation of Neisseria
gonorrhoeae in samples positive according to the COBAS AMPLICOR Chlamydia trachomatis ⁄Neisseria
gonorrhoeae PCR assay. The new assay ampliﬁes 375 bp of the N. gonorrhoeae 16S rRNA gene and
includes an internal ampliﬁcation control introduced during DNA puriﬁcation. The assay had 100%
speciﬁcity because of the high speciﬁcity of the HybProbes and primers. Other Neisseria spp. failed to
generate positive crossing-point values and melting peaks. The analytical sensitivity for N. gonorrhoeae
DNA was 0.5 fg ⁄PCR, corresponding to 0.3 CFU ⁄PCR. Sensitivity was not impaired in the presence of
higher DNA concentrations (‡1000-fold) from Neisseria spp. other than N. gonorrhoeae. The sensitivity
was similar to that reported for the COBAS AMPLICOR assay with cervical swab samples. To assess its
clinical applicability as a conﬁrmatory test, 38 (2.9%) of 1313 swabs that were positive according to the
COBAS AMPLICOR assay were tested using the new in-house assay and the commercially available
GenFlow Neisseria test. Twenty-one samples negative according to COBAS AMPLICOR also underwent
conﬁrmatory testing. Both conﬁrmatory tests yielded identical results; the 21 negative samples remained
negative, and only 11 (28.9%) of the samples positive according to COBAS AMPLICOR were positive
after retesting, suggesting a low prevalence (0.84%) of N. gonorrhoeae infection in the study population.
These data suggest that the novel real-time PCR assay is an excellent and easy to interpret conﬁrmatory
test for the existing COBAS AMPLICOR assay for N. gonorrhoeae.
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INTRODUCTION
Neisseria gonorrhoeae causes one of the most
prevalent sexually transmitted bacterial infec-
tions found in men and women. Culture is still
used by many laboratories for diagnosis, but it
has been shown that nucleic acid ampliﬁcation-
based tests (NAATs) are more sensitive [1,2]. At
present, several commercially available NAATs
are used for screening purposes, including the
ProbeTec ET System, based on strand displace-
ment ampliﬁcation technology, the APTIMA
Combo 2 assay, based on transcription-mediated
ampliﬁcation, and the COBAS AMPLICOR
Chlamydia trachomatis ⁄Neisseria gonorrhoeae (CA
CT ⁄NG) test, which is based on PCR and
hybridisation capture [3]. The CA CT ⁄NG test is
probably the most widely used PCR-based assay
for C. trachomatis and N. gonorrhoeae, because of
its excellent sensitivity and ease of use. The
NG component of this test targets the cytosine
DNA methyltransferase gene of N. gonorrhoeae,
but has been shown to cross-react with certain
strains of Neisseria subﬂava, Neisseria cinerea,
Neisseria ﬂavescens, Neisseria lactamica, Neisseria
sicca and Lactobacillus spp. belonging to the
commensal ﬂora of the human respiratory and
genital tract. Therefore, a second test is necessary
to conﬁrm the diagnosis.
Corresponding author and reprint requests: C. Schabereiter-
Gurtner, Department of Clinical Microbiology, University
Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna,
Austria
E-mail: Claudia.Schabereiter-Gurtner@meduniwien.ac.at
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases
The present study describes the development of
a conﬁrmatory real-time PCR assay targeting the
16S rRNA gene of N. gonorrhoeae. The assay was
evaluated with pure cultures and with cervical
swabs spiked with N. gonorrhoeae DNA. The
results of a clinical evaluation were compared
with the newly available GenFlow Neisseria test,
which is based on a PCR followed by hybridisa-
tion on lateral ﬂow dipsticks.
MATERIALS AND METHODS
Bacterial strains
DNA of N. gonorrhoeae (ATCC 31426 and 33 clinical isolates),
N. cinerea (ATCC 14685), Neisseria meningitidis (ATCC 13090),
Neisseria mucosa (ATCC 19695), Neisseria polysaccharea (CCUG
18030T) and Neisseria perﬂava (DSM 18009) was extracted
using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol for the isolation of
genomic DNA from bacterial cultures.
Screening of swabs with the CA CT ⁄NG test
In total, 1313 vaginal and cervical swabs collected between
May 2003 and December 2006 from both symptomatic and
asymptomatic patients at the Department of Clinical Micro-
biology, Institute of Hygiene and Medical Microbiology,
Medical University Vienna were screened for N. gonorrhoeae
using the CA CT ⁄NG test (Roche, Mannheim, Germany).
Swabs were swirled in the transport medium contained in the
STD Swab Specimen Collection and Transport Kit (Roche)
and were then removed according to the recommendations of
the manufacturer. In the laboratory, the transport medium
was mixed with 1 mL of the CT ⁄NG DIL buffer provided in
the CA CT ⁄NG test kit; the mixture of transport medium and
CT ⁄NG DIL buffer is designated TMD-mix in the present
study. For PCR, 50 lL of TMD-mix was used as template
DNA in the CA CT ⁄NG assay, which was performed accord-
ing to the manufacturer’s instructions. The original cut-off
value recommended by the manufacturer (A660 ‡ 0.2) was
used.
Preparation of DNA for conﬁrmatory tests
Conﬁrmatory tests used the same swab sample that was
used for the CA CT ⁄NG assay. Puriﬁcation of DNA was
recommended by the manufacturer of the GenFlow
Neisseria test (Demeditec, Kiel, Germany), and was also
necessary for the real-time PCR, since the TMD-mix con-
tained inhibitory substances. An internal control (see below)
(10 fg) was added to 200 lL of TMD-mix before puriﬁcation.
DNA was puriﬁed using a HighPure PCR Template
Preparation Kit (Roche) and was eluted with 50 lL of
elution buffer.
GenFlow Neisseria test
For the GenFlow Neisseria test, 15 lL of the puriﬁed DNA
extract was used as template DNA. PCR was performed in a
Biometra TRIO-Thermoblock (Biometra, Go¨ttingen, Germany),
with N. gonorrhoeae-speciﬁc PCR product being detected using
the lateral ﬂow dipsticks supplied with the test in accordance
with the manufacturer’s instructions.
Preparation of the internal control
An internal control (ICO) was designed to be co-ampliﬁed
with the 16S rRNA Ngo assay (see below) in order to exclude
the possibility of false-negative results caused by PCR
inhibition. A 120-bp oligonucleotide (GGCTGAAAGATGAG
CTCGAGAGTTCGACCAAATCCGTTGACTCCGACCTGCT
GCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCA
AGCTATCATCAGTCCGCTGTGCTTTGAGA), synthesised
by VBC-Genomics (Vienna, Austria), contained primer anneal-
ing sites for primers ICO-F (5¢-GGCTGAAAGATGAGCTCGA
GAG) and ICO-R (5¢-TCTCAAAGCACAGCGGACTG), and
binding sites for HybProbes ICO-S1 and ICO-S2 (see below).
PCR ampliﬁcation used primers ICO-F and ICO-R in a
Robocycler (Stratagene, La Jolla, CA, USA), with PCR condi-
tions comprising 5 min at 95C, followed by 30 cycles of 1 min
at 95C, 1 min at 55C and 1 min at 72C, with a ﬁnal extension
of 5 min at 72C. The PCR product was then cloned using the
pGEM-T Easy Vector System (Promega, Vienna, Austria)
according to the manufacturer’s instructions. The resulting
plasmid (ICO plasmid) was puriﬁed using a Plasmid Miniprep
Kit (Qiagen). The DNA concentration of the plasmid was
assessed by UV spectrophotometry.
The lowest detectable ICO plasmid concentration was
determined on the basis of ten-fold serial dilutions in the
range between 1 pg (equivalent to c. 30 000 copies) and
0.001 fg (equivalent to c. 0.3 copies). In addition, 50-fg aliquots
of N. gonorrhoeae DNA were spiked with ten-fold serial
dilutions of the ICO plasmid in the range between 1 pg and
0.1 fg to determine the effect of ICO ampliﬁcation on the
sensitivity of the assay. To determine the optimal amount of
ICO plasmid to be spiked to the sample before DNA
extraction, ten-fold serial dilutions in the range between 1 pg
and 0.01 fg were added to 200 lL of TMD-mix prepared from
ﬁve negative vaginal swabs before DNA extraction and real-
time PCR.
16S rRNA Ngo assay
Two assays using different reverse primers were designed.
The 16S rRNA Ngo-R1 assay contained primer Ngo-R1 (see
below), which was highly speciﬁc for N. gonorrhoeae and
ampliﬁed 375 bp of the 16S rRNA gene of N. gonorrhoeae.
The 16S rRNA Ngo-R2 assay contained primer Ngo-R2 (see
below), which was speciﬁc for the genus Neisseria and
ampliﬁed a 212-bp product. To exclude false-negative PCR
results caused by PCR inhibition, the ICO plasmid was co-
ampliﬁed in a multiplex PCR. All reactions were performed in
duplicate. The PCR mixtures contained 2 lL of LightCycler-
FastStart DNA Master Kit Hybridization Probes (Roche),
4 mM MgCl2, 5 pmoL primer Ngo-F (5¢-GCGTGTCTGAA
GAAGGC), 5 pmoL primer Ngo-R1 (5¢-ACCCACGCTTT
CGGAC) or 5 pmoL primer Ngo-R2 (5¢-GGGATTTCACA
TCCTGCT), 4 pmoL HybProbe Ngo-S1 (5¢-LC Red 640-GCC
TTTTCTTCCCTGACAAAAGTCCT-phosphate), 4 pmoL
HybProbe Ngo-S2 (5¢-GGCCGCCGATATTGGCAA-ﬂuores-
cein), 3 pmoL primer ICO-F, 3 pmoL primer ICO-R, 2 pmoL
HybProbe ICO-S1 (5¢-GCTGCATACGCTTGATCCGGCT-
ﬂuorescein), 2 pmoL HybProbe ICO-S2 (5¢-LC Red
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705-CCTGCCCATTCGACCACCAAGC-phosphate) and 5 lL
DNA extract. The reaction mixtures were made up to a ﬁnal
volume of 20 lL with distilled water. Primers and probes were
synthesised by Metabion (Martinsried, Germany).
A touchdown PCR was performed using the LightCycler
v.1.2 instrument (Roche), with initial denaturation for 10 min
at 95C, followed by 45 cycles (with a temperature transition
rate of 20C ⁄ s) of 5 s at 95C, 10 s starting at 65C and
decreasing 0.2C by every cycle to 62C, and 10 s at 72C, with
a single ﬂuorescence acquisition step at the ﬁnal annealing.
Ampliﬁcation was followed by melting point analysis of the
probe–PCR product duplex, comprising 95C for 2 s, cooling
to 45C for 1 min, and then increasing the temperature to 95C
at a rate of 0.2C ⁄ s with continuous ﬂuorescence acquisition.
A ﬁnal cooling step was performed at 40C for 10 s. Data
acquisition was performed in channel F2 for the N. gonorrhoeae
rDNA products and channel F3 for the ICO DNA products.
A colour compensation ﬁle for the LC Red 640 and LC Red 705
dyes was generated according to the manufacturer’s instruc-
tions and was used in all PCR runs. Crossing-point (Cp) values
were determined and melting curves were constructed auto-
matically using the LightCycler software (v.3.5.3). Samples
were considered to be positive if they yielded an ampliﬁcation
curve and had a characteristic melting temperature (Tm) value
in channel F2. PCR inhibition was excluded by the presence of
an ampliﬁcation curve in channel F3.
In order to avoid contamination and to exclude the
possibility of false-positive PCR results through cross-contam-
ination, all manipulations were performed using aerosol-
resistant tips. DNA extraction, preparation of the mastermix
and the addition of template were performed in separate
rooms. During DNA extraction, a sample preparation control
was performed, in which water instead of sample material was
used, and a reagent control with sterile water as the template
was also included in each PCR run.
Analytical evaluation
The speciﬁcity of the primers and probes was checked using
the databases provided at the National Center for Biotechnol-
ogy Information (http://www.ncbi.nlm.nih.gov/). Ribosomal
sequences of N. gonorrhoeae, other Neisseria spp. and other
members of the Neisseriaceae were aligned with the primers
and probes using the ClustalW multiple sequence alignment
program provided by the European Bioinformatics Institute
(http://www.ebi.ac.uk/clustalw/). BLAST searches were also
performed (http://www.ncbi.nlm.nih.gov/BLAST/). In addi-
tion to the sequence analyses, the speciﬁcity of the 16S rRNA
Ngo-R1 and 16S rRNA Ngo-R2 assays was investigated by
testing DNA extracted from isolates of N. cinerea, N. gonor-
rhoea, N. meningitidis, N. mucosa, N. perﬂava and N. polysacch-
area.
Part of the 16S rRNA gene of N. gonorrhoeae strain NG19
(this study) was ampliﬁed and sequenced using primers 27-F
and 1100-R [4] in conjunction with an ABI PRISM 310 and
BigDye chemistry, in accordance with the recommendations
of the manufacturer (Applied Biosystems, Foster City, CA,
USA).
In order to exclude the possibility of a decrease in
sensitivity from competitive ampliﬁcation of Neisseria spp.
other than N. gonorrhoeae that may be present in a sample,
50 fg of N. gonorrhoeae DNA spiked with DNA dilutions
(5 ng ⁄PCR, 500 pg ⁄PCR, 50 pg ⁄PCR, 5 pg ⁄PCR, 500 fg ⁄PCR,
50 fg ⁄PCR and 5 fg ⁄PCR) of N. cinerea and N. meningitidis,
respectively, were tested with both the 16S rRNA Ngo-R1
assay and the 16S rRNA Ngo-R2 assay.
Further analytical evaluation was performed only with the
16S rRNA Ngo-R1 assay. The efﬁciency of the 16S rRNA
Ngo-R1 assay was determined from standard curves con-
structed from ten-fold serial dilutions (100 pg to 0.1 fg) of
genomic DNA of N. gonorrhoeae. In order to determine the
analytical sensitivity (deﬁned as the lowest detectable con-
centration) and the limit of detection (deﬁned as the concen-
tration at which 95% of repeated PCR results were positive)
[5], N. gonorrhoeae DNA (500, 50, 25, 5 and 0.5 fg) combined
with the DNA extract of a negative sample was analysed. The
TMD-mix was spiked with 10 fg of ICO plasmid before
extraction. PCR was performed in duplicate on ten different
days. The sensitivities of the 16S rRNA Ngo-R1 assay and the
CA CT ⁄NG test were also compared directly using spiked
sample material; thus, 1 mL of TMD-mix of a negative swab
was spiked with 10 fg of ICO plasmid and 500, 200, 100, 50 or
5 fg of N. gonorrhoeae DNA. For the CA CT ⁄NG test, a 50-lL
aliquot was used directly as template DNA. For real-time
PCR, 200 lL of the spiked material was extracted and eluted
in 50 lL of elution buffer, and 5 lL of the eluate was used as
template DNA.
RESULTS
Analytical evaluation
Sequence analyses revealed that primer Ngo-R1
was highly speciﬁc for N. gonorrhoeae, with at
least one mismatch with other Neisseria spp. near
the 3¢-end, while primer Ngo-R2 showed 100%
sequence homology with the genus Neisseria.
HybProbe Ngo-S2 was 100% speciﬁc for N. gon-
orrhoeae, which ensured 100% assay speciﬁcity.
Fig. S1 (see Supplementary material) shows the
sequence alignment of primers and probes used
in the 16S rRNA-R1 assay with the 16S rRNA
gene of seven strains of N. gonorrhoeae, 19 other
Neisseria spp. and nine unclassiﬁed Neisseria spp.
contained in the EMBL database.
Isolates of N. cinerea, N. meningitidis, N. mucosa,
N. perﬂava and N. polysaccharea did not generate
positive Cp values and melting peaks with the
16S rRNA Ngo-R1 assay or the 16S rRNA Ngo-R2
assay (Table 1). Each of the 34 N. gonorrhoeae
isolates tested generated positive Cp values. Of
these, 33 isolates had melting peaks at 67C, while
one isolate (NG19) generated an aberrant melting
peak at 64C. Sequence analysis of this isolate
revealed a single base-pair mismatch at the
binding site of probe Ngo-S1 (Fig. S1). The 16S
rRNA gene sequence of this strain has been
submitted to GenBank under accession number
EU233796.
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Table 1 also shows the results of the titration
experiments in which 50 fg of N. gonorrhoeae
DNA was spiked with different concentrations
of N. cinerea and N. meningitidis DNA. Experi-
ments with the 16S rRNA Ngo-R1 assay revealed
that the sensitivity of the assay was not affected
when N. cinerea DNA was added at up to a
100 000-fold greater concentration than the con-
centration of N. gonorrhoeae DNA. N. cinerea had
two mismatches at the binding site of primer
Ngo-R1 (Fig. S1). In contrast, an N. meningitidis
DNA concentration that was 100-fold greater than
that of N. gonorrhoeae DNA partially inhibited the
16S rRNA Ngo-R1 assay, resulting in a decrease
in ﬂuorescence of the ampliﬁcation curve. N. men-
ingitidis DNA concentrations that were ‡1000-fold
greater than that of N. gonorrhoeae DNA inhibited
the assay completely. N. meningitidis had one
mismatch at the binding site of primer Ngo-R1
(Fig. S1). Experiments with the 16S rRNA Ngo-R2
assay revealed that concentrations of N. cinerea or
N. meningitidis DNA that were ten-fold greater
than that of N. gonorrhoeae DNA inhibited the
assay completely.
Further evaluation of the 16S rRNA Ngo-R1
assay revealed a slope of 3.378, indicating a high
ampliﬁcation efﬁciency and a lowest detect-
able concentration of N. gonorrhoeae DNA of
0.5 fg ⁄PCR, equivalent to 0.3 CFU ⁄PCR, although
only 13 (65%) of the 20 repeated PCRs performed
on ten different days were positive at this con-
centration. The limit of detection of 5 fg corre-
sponded to 3 CFU ⁄PCR, which is similar to the
sensitivity of 5 CFU ⁄PCR reported by the manu-
facturer for the CA CT ⁄NG test. Comparison of
the 16S rRNA Ngo-R1 assay and the CA CT ⁄NG
test with spiked samples also showed identical
sensitivities of 50 fg ⁄TMD-mix.
The lowest detectable ICO plasmid DNA con-
centration was 0.01 fg (equivalent to c. 3 copies),
which was detected at Cp 41.0. The titration
experiments with 50 fg of N. gonorrhoeae DNA
and ten-fold serial dilutions (1 pg to 0.1 fg) of the
ICO plasmid revealed that co-ampliﬁcation of the
ICO in concentrations up to 1 fg of ICO plas-
mid ⁄PCR (equivalent to c. 300 copies) did not
affect the sensitivity of the 16S rRNA Ngo-R1
assay. At concentrations of >1 fg of ICO plas-
mid ⁄PCR, inhibition of ampliﬁcation of N. gonor-
rhoeae DNA was observed. The lowest detectable
ICO plasmid concentration after DNA extraction
was 1 fg ⁄ 200 lL of TMD-mix in all ﬁve negative
vaginal swabs that were tested. The optimal
amount of ICO plasmid that ensured reproduc-
ible detection of the ICO without reducing the
overall sensitivity of the 16S rRNA Ngo assay was
10 fg ⁄ 200 lL of TMD-mix, corresponding to
c. 1 fg of ICO plasmid ⁄PCR.
Conﬁrmation of CA CT ⁄NG test results
Between May 2003 and December 2006, 1313
swabs were tested for N. gonorrhoeae, using the
CA CT ⁄NG test. Of these, 38 (2.9%) swabs were
Table 1. Detection of Neisseria gonorrhoeae in the presence of other Neisseria spp.
Template Cp value of 16S rRNA Ngo-R1 assay Cp value of 16S rRNA Ngo-R2 assay
5 ng of Neisseria cinerea + 50 fg of N. gonorrhoeae 37.7 Negative
500 pg of N. cinerea + 50 fg of N. gonorrhoeae 38.4 Negative
50 pg of N. cinerea + 50 fg of N. gonorrhoeae 38.4 Negative
5 pg of N. cinerea + 50 fg of N. gonorrhoeae 38.0 Negative
500 fg of N. cinerea + 50 fg of N. gonorrhoeae 37.8 37.5
50 fg of N. cinerea + 50 fg of N. gonorrhoeae 38.5 37.0
5 fg of N. cinerea + 50 fg of N. gonorrhoeae 37.5 38.1
5 ng of Neisseria meningitidis + 50 fg of N. gonorrhoeae Negative Negative
500 pg of N. meningitidis + 50 fg of N. gonorrhoeae Negative Negative
50 pg of N. meningitidis + 50 fg of N. gonorrhoeae 37.1 Negative
5 pg of N. meningitidis + 50 fg of N. gonorrhoeae 39.3 Negative
500 fg of N. meningitidis + 50 fg of N. gonorrhoeae 37.9 37.1
50 fg of N. meningitidis + 50 fg of N. gonorrhoeae 37.9 36.1
5 fg of N. meningitidis + 50 fg of N. gonorrhoeae 39.0 36.9
50 fg of N. gonorrhoeae 37.7 36.6
5 ng of N. cinerea Negativea Negativea
5 ng of N. meningitidis Negativea Negativea
5 ng of Neisseria mucosa Negativea Negativea
5 ng of Neisseria perﬂava Negativea Negativea
5 ng of Neisseria polysaccharea Negativea Negativea
Reagent control Negative Negative
aNo melting peak was generated in the melting curve analysis.
Cp, crossing-point value (the number of PCR cycles required to generate a positive result) in the LightCycler instrument.
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presumptively positive for N. gonorrhoeae and
underwent conﬁrmatory testing, using the
in-house 16S rRNA Ngo-R1 and Ngo-R2 assays
and the GenFlow Neisseria test. In order to test
the speciﬁcity, 21 CA NG-negative samples were
also retested (Table 2). The 16S rRNA Ngo-R1
assay and the GenFlow Neisseria test yielded
identical results, in that the 21 CA NG-negative
samples remained negative and only 11 (28.9%)
of the 38 CA NG-positive samples were con-
ﬁrmed as positive. These results suggested a
prevalence of 0.84% for N. gonorrhoeae in the
study population. The 16S rRNA Ngo-R1 assay
detected N. gonorrhoeae-speciﬁc DNA at Cp val-
ues between 21.6 and 38.0. None of the samples
showed PCR inhibition, and the ICO plasmid was
detected at Cp values between 37.0 and 40.0.
Using the 16S rRNA Ngo-R2 assay, one swab that
was positive according to the 16S rRNA Ngo-R1
assay and the GenFlow Neisseria test repeatedly
remained negative. Sequencing and BLAST anal-
ysis of the PCR product revealed a sequence
corresponding to Neisseria ﬂava. This ﬁnding
suggests that the N. gonorrhoeae-speciﬁc sequence
was probably not ampliﬁed by the Ngo-R2 assay
because of the presence of high numbers of
another Neisseria sp.
DISCUSSION
The low positive predictive value of the
CA CT ⁄NG test means that positive results must
be conﬁrmed by a second NAAT that utilises an
alternative target to the cytosine DNA methyl-
transferase gene of N. gonorrhoeae, as recom-
mended by the CDC [6]. In addition to
commercial screening tests, several in-house
PCR assays for the detection of N. gonorrhoeae
have been described. These assays target the gyrA
gene [7], the cppB gene on the 2.6-MDa cryptic
plasmid [8–12], the porA pseudogene [13–15], the
opa gene [15–17], the orf1 gene [18], and the 16S
rRNA [7,12,19–23]. However, some of these tests
lack sensitivity and ⁄ or speciﬁcity [3]. Studies with
PCR assays targeting the porA pseudogene and
the opa gene have revealed high speciﬁcity
[14,15,17], while assays targeting the gyrA gene
have shown cross-reactivity with N. subﬂava and
possible competitive inhibition of N. gonorrhoeae
ampliﬁcation by other Neisseria spp. [3,7]. Assays
targeting the cppB gene have revealed that this
gene is present in some commensal Neisseria spp.,
but is absent in c. 6% of N. gonorrhoeae isolates
[8,19,20]. Assays targeting the 16S rRNA gene
have also shown varying results. A conventional
PCR assay described by Airell et al. [7] showed a
lack of speciﬁcity and sensitivity. A 16S rRNA
assay, provided originally by Roche, was based
on an enzyme immunoassay system in which
PCR amplicons were detected using microwell
plates coated with a N. gonorrhoeae-speciﬁc DNA
probe [12,21–23], but this assay has been with-
drawn from the market. Two real-time PCR
assays targeting the 16S rRNA gene have been
described to date [19,20], but these assays were
not internally controlled and also allowed the
ampliﬁcation of Neisseria spp. other than N. gon-
orrhoeae. These tests may also be more prone to
yield false-negative results because of competitive
inhibition of the ampliﬁcation of N. gonorrhoeae.
The social impact of false-positive test results is
such that conﬁrmatory tests for N. gonorrhoeae
must provide 100% speciﬁcity. The 16S rRNA
gene was chosen as the target for the conﬁrmatory
assay presented in this study because it is a
universal bacterial gene found in all N. gonor-
rhoeae strains, which excludes the possibility of
false-negative results because of a missing PCR
target in certain N. gonorrhoeae subtypes. Titration
studies with DNA from other Neisseria spp.
revealed that concentrations greater than ten-fold
that of N. gonorrhoeae could result in competitive
ampliﬁcation and false-negative results when
performing real-time PCR with primers 100%
speciﬁc for the genus Neisseria. Similar observa-
tions were made by Mangold et al. [19], using
concentrations >40-fold that of N. gonorrhoeae
with genus-speciﬁc primers. Therefore, only the
species-speciﬁc system of primers and probes in
the 16S rRNA Ngo-R1 assay, used in combination
with stringent ampliﬁcation conditions, ensured
detection of N. gonorrhoeae strains in the presence
of large numbers of other Neisseria spp. This is of
Table 2. Results of evaluation of real-time PCR analysis
and the GenFlow Neisseria test for clinical samples
Assay
CA NG-positive
samples (n = 38)
CA NG-negative
samples (n = 21)
Positive Negative Positive Negative
16S rRNA Ngo-R1 assay 11 27 0 21
16S rRNA Ngo-R2 assay 10 28 0 21
GenFlow Neisseria test 11 27 0 21
CA NG, COBAS AMPLICOR Neisseria gonorrhoeae assay.
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importance, as the presence of other Neisseria spp.
has been shown to be the reason for false-positive
results obtained with the CA CT ⁄NG test.
A low limit of detection in conﬁrmatory tests is
also of crucial importance. In the present study,
the 16S rRNA Ngo assay was revealed to be at
least as sensitive as the CA CT ⁄NG test, thereby
excluding the possibility of false-negative results
occurring during conﬁrmatory testing because of
reduced sensitivity. An ICO, introduced into the
assay at the DNA puriﬁcation stage, further
increased the reliability of PCR-negative results
by simultaneously serving as a DNA extraction
control and a PCR inhibition control. The amount
of ICO in the reaction mixture was kept as low as
possible to minimise competition with N. gonor-
rhoeae DNA in low-titre samples, which would
otherwise have an impact on the sensitivity of the
16S rRNA Ngo assay. Data obtained with the
GenFlow Neisseria test were identical to those
obtained using this in-house test, suggesting that
the commercial GenFlow Neisseria test is also
suitable as a conﬁrmatory test for CA NG-
positive samples. However, this test does not
include an ICO and requires post-ampliﬁcation
handling for detection of PCR products, which, in
contrast to the LightCycler system, can signiﬁ-
cantly increase the possibility of PCR carryover
contamination.
The high false-positive rate associated with the
CA CT ⁄NG test demonstrated the importance of
conﬁrming all CA NG-positive results with a
supplementary assay. The prevalence of infection
in the subject population was 0.84% during the
study period. The ‘true-positive’ percentage of
28.9% is similar to that reported by Boel et al. [20]
and Geraats-Peters et al. [16], but is lower than
that reported from other studies, which showed a
true-positive rate of ‡56% [17,19,21]. The present
data suggest that the in-house real-time PCR
assay is a highly speciﬁc, sensitive, fast and easy-
to-interpret test, and that it may therefore repre-
sent an excellent supplementary assay for use in
conjunction with the CA CT ⁄NG test.
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